Anteris Technologies Ltd
ASX:AVR

Watchlist Manager
Anteris Technologies Ltd Logo
Anteris Technologies Ltd
ASX:AVR
Watchlist
Price: 9.3 AUD -3.93% Market Closed
Market Cap: 196.6m AUD
Have any thoughts about
Anteris Technologies Ltd?
Write Note

Anteris Technologies Ltd
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Anteris Technologies Ltd
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Anteris Technologies Ltd
ASX:AVR
Cash Equivalents
AU$11.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Nanosonics Ltd
ASX:NAN
Cash Equivalents
AU$2.1m
CAGR 3-Years
-20%
CAGR 5-Years
15%
CAGR 10-Years
N/A
Polynovo Ltd
ASX:PNV
Cash Equivalents
AU$24.2m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SDI Ltd
ASX:SDI
Cash Equivalents
AU$6.3m
CAGR 3-Years
-16%
CAGR 5-Years
-1%
CAGR 10-Years
5%
Ansell Ltd
ASX:ANN
Cash Equivalents
$185.5m
CAGR 3-Years
-7%
CAGR 5-Years
-14%
CAGR 10-Years
-5%
Next Science Ltd
ASX:NXS
Cash Equivalents
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Anteris Technologies Ltd
Glance View

Market Cap
178.8m AUD
Industry
Health Care

Anteris Technologies Ltd. is a structural heart company, researches, develops, commercializes, and distributes various medical technologies and devices. The company is headquartered in Toowong, Queensland. The company went IPO on 2004-03-24. The firm is engaged in delivering solutions that help healthcare professionals. The firm operates through two segments: operations and projects. Operation segment provides Bio implant ADAPT operations inclusive of manufacturing and sales. Project segment includes Transcatheter Aortic Valve Replacement (TAVR), which is developed using ADAPT 3D single-piece technology and other development projects across the Company. The company offers two products, ADAPT and DurAVR. ADAPT technology is a BioScaffold, which is a tissue technology platform that demonstrates zero calcification. xenograft tissue into a pure collagen scaffold with optimized strength and pliability, biocompatibility and unparalleled durability. DurAVR heart valve Is focused on delivering a functional cure in the treatment of Severe Aortic Stenosis.

AVR Intrinsic Value
0.76 AUD
Overvaluation 92%
Intrinsic Value
Price

See Also

What is Anteris Technologies Ltd's Cash Equivalents?
Cash Equivalents
11.8m AUD

Based on the financial report for Dec 31, 2023, Anteris Technologies Ltd's Cash Equivalents amounts to 11.8m AUD.

What is Anteris Technologies Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 1Y
13 203%

Over the last year, the Cash Equivalents growth was 13 203%.

Back to Top